Eli Lily 2025Q3 Analysis

Buffett-Style Value Investment Analysis: Eli Lilly (LLY)

1️⃣ Circle of Competence Analysis

1.1 Is the Company's Business Easy to Understand?

• Products: Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products [ref_1]. Its portfolio is concentrated in high-demand therapeutic areas: Diabetes & Obesity (Mounjaro, Zepbound, Trulicity), Oncology (Verzenio), Immunology (Taltz), and Neuroscience [ref_2].
• Customers: The primary customers are wholesale distributors (McKesson, Cencora, Cardinal Health), pharmacy benefit managers (PBMs), and healthcare providers, ultimately serving patients [ref_3].
• Clarity: The business model is straightforward: invest heavily in R&D to create patented medicines, manufacture them, and sell them at high margins. The financial structure is non-financialized and transparent.

1.2 Is the Company's Business Logic Clear for the Next 10 Years?

• Industry Stage: The pharmaceutical industry is mature but undergoing a massive growth phase in the metabolic (obesity/diabetes) space.
• Growth Trajectory: Demand is exploding. Revenue for the first nine months of 2025 grew 46% year-over-year [ref_4]. The company is currently in a "super-cycle" driven by incretin medicines (GLP-1s).
• Predictability: While individual patent cliffs are a risk, the patent protection for its core growth drivers (Mounjaro/Zepbound) extends well into the next decade (2036–2040) [ref_5].

📌 Conclusion (In/Out of Circle of Competence): IN. While pharmaceutical science is complex, the economic characteristics of selling patent-protected, essential medicines for chronic conditions are highly predictable and understandable.

2️⃣ Durable Competitive Advantage (The Moat)

2.1 Brand & Pricing Power

• Pricing: The company possesses significant pricing power derived from intellectual property. Gross margin is exceptionally high, standing at 80.9% for the first nine months of 2025 [ref_6].
• Brand: Mounjaro and Zepbound have rapidly become household names, creating strong consumer pull despite being prescription drugs.

2.2 Cost & Scale Advantage

• Supply Chain Moat: The manufacturing of incretin medicines (GLP-1) involves complex aseptic processes. Lilly is deploying massive capital (approx. $9 billion committed in executed agreements) to expand capacity [ref_7]. This creates a barrier to entry for smaller competitors who cannot match this capital intensity.
• Margins: The gross margin improved by 2.4 percentage points in 2025 due to favorable product mix and improved production costs [ref_8].

2.3 Switching Costs

• High: Patients on chronic therapies for diabetes, obesity, and oncology rarely switch away from effective treatments due to health risks and insurance formulary lock-ins.

2.4 Legal Monopoly (Patents)

• Strong Protection: The "Moat" is primarily legal.
  • Mounjaro/Zepbound (Tirzepatide): Compound patent expires in 2036 (U.S.) and 2040 (Japan) [ref_5].
  • Verzenio: Compound patent expires in 2031 (U.S.) [ref_9].
  • Risk: Trulicity is approaching a patent cliff (2027 in the U.S.), but Mounjaro is successfully replacing it [ref_5].

📌 Overall Competitive Advantage Judgment: Strong Moat. Driven by a "wide" patent moat on blockbuster drugs and a "deep" capital moat in manufacturing capacity.

3️⃣ Management

3.1 Is the Management Team Ethical (Integrity)?

• Transparency: Management is transparent about risks, including manufacturing shortages and litigation regarding pricing [ref_10]. There are no reports of material accounting irregularities in the filings.
• Compliance: The company maintains a standard code of conduct. While there are ongoing lawsuits regarding product liability and pricing (common in Pharma), they appear to be industry-standard risks rather than management malfeasance [ref_11].

3.2 Is the Management Team Capable (Execution)?

• Strategy: CEO David Ricks has successfully pivoted the company toward the highest-growth areas (Obesity/Alzheimer's).
• Execution: The execution of the Mounjaro/Zepbound launch has been historic. Revenue surged from $34.1 billion in 2023 to $45.9 billion in just the first nine months of 2025 [ref_12].
• Capital Allocation: Management is aggressively investing in production capacity ($5.8 billion in CapEx YTD 2025) to capture demand, which is the correct long-term move [ref_13].

3.3 Is Management's Interest Highly Aligned with Shareholders?

• Returns: Management continues to return capital via dividends ($4.04 billion YTD 2025) and share repurchases ($2.6 billion YTD 2025) despite heavy reinvestment needs [ref_14].

📌 Overall Management Rating: Excellent.

4️⃣ Financials

4.1 Profitability

• Gross Margin: consistently elite. 79.2% (2024) $\rightarrow$ 82.9% (Q3 2025) [ref_15].
• Net Margin: Volatile due to IPR&D (Acquired In-Process R&D) charges, but underlying profitability is robust. Net income more than doubled in 2024 vs 2023 ($10.6B vs $5.2B) [ref_16].

4.2 Returns

• ROE: Net Income for the trailing twelve months is approx. $18.4B (based on 9-month 2025 data annualized). With Shareholder Equity at $23.8B [ref_17], ROE is astronomical (~77%), indicating immense capital efficiency despite heavy asset investment.

4.3 Free Cash Flow (FCF)

• Trend: Operating Cash Flow was $13.6B for the first 9 months of 2025 [ref_18]. Even after deducting a massive $5.3B in CapEx [ref_19], FCF is positive and rapidly growing.

4.4 Capital Structure

• Leverage: Total Debt increased to $42.5B in 2025 (up from $33.6B in 2024) to fund expansion and acquisitions [ref_20].
• Solvency: Cash & Equivalents are $9.8B [ref_21]. While debt is high, the interest coverage is comfortable given the exploding operating income.

4.5 Shareholder Returns

• Dividends: Consistent increases. Annual rate indicated at $6.00 per share for 2025 [ref_22].
• Buybacks: $15 billion repurchase program authorized in Dec 2024; $2.6 billion repurchased in first 9 months of 2025 [ref_14].

📌 Overall Financial Assessment: Exceptional. The company is a cash-generating machine, currently leveraging its balance sheet to fund a generational growth opportunity.

5️⃣ Intrinsic Value

(The following content is exclusive to subscribers.)